1. Home
  2. RYTM vs VEON Comparison

RYTM vs VEON Comparison

Compare RYTM & VEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • VEON
  • Stock Information
  • Founded
  • RYTM 2008
  • VEON 1992
  • Country
  • RYTM United States
  • VEON United Arab Emirates
  • Employees
  • RYTM N/A
  • VEON N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • VEON Telecommunications Equipment
  • Sector
  • RYTM Health Care
  • VEON Telecommunications
  • Exchange
  • RYTM Nasdaq
  • VEON Nasdaq
  • Market Cap
  • RYTM 4.3B
  • VEON 2.7B
  • IPO Year
  • RYTM 2017
  • VEON 1996
  • Fundamental
  • Price
  • RYTM $65.25
  • VEON $43.08
  • Analyst Decision
  • RYTM Strong Buy
  • VEON Strong Buy
  • Analyst Count
  • RYTM 12
  • VEON 1
  • Target Price
  • RYTM $77.50
  • VEON $60.00
  • AVG Volume (30 Days)
  • RYTM 585.3K
  • VEON 288.0K
  • Earning Date
  • RYTM 08-05-2025
  • VEON 08-07-2025
  • Dividend Yield
  • RYTM N/A
  • VEON N/A
  • EPS Growth
  • RYTM N/A
  • VEON N/A
  • EPS
  • RYTM N/A
  • VEON 6.56
  • Revenue
  • RYTM $136,863,000.00
  • VEON $4,088,000,000.00
  • Revenue This Year
  • RYTM $37.56
  • VEON $6.27
  • Revenue Next Year
  • RYTM $74.99
  • VEON $6.79
  • P/E Ratio
  • RYTM N/A
  • VEON $7.03
  • Revenue Growth
  • RYTM 48.88
  • VEON 8.84
  • 52 Week Low
  • RYTM $40.46
  • VEON $25.48
  • 52 Week High
  • RYTM $69.89
  • VEON $58.30
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 53.08
  • VEON 48.25
  • Support Level
  • RYTM $60.80
  • VEON $38.08
  • Resistance Level
  • RYTM $64.00
  • VEON $46.46
  • Average True Range (ATR)
  • RYTM 1.96
  • VEON 2.97
  • MACD
  • RYTM -0.13
  • VEON 0.39
  • Stochastic Oscillator
  • RYTM 44.48
  • VEON 73.83

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About VEON VEON Ltd. ADS

VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan.

Share on Social Networks: